Pharma BD Deal Intelligence
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →Roche and Atea Pharmaceuticals will jointly develop AT-527, a Phase 2 oral antiviral for COVID-19, under a deal worth up to 1.35 billion dollars announced…
Roche has struck a deal worth up to 1.35 billion dollars with Atea Pharmaceuticals for an oral COVID-19 antiviral that the companies hope can be deployed…
Roche has officially terminated the 1.35 billion dollar collaboration with Atea Pharmaceuticals on AT-527 after the oral antiviral missed its primary endpoint…
Source summaries from our enrichment pipeline; follow links for originals.
All 10 sources with sentiment breakdown →
Atea Pharmaceuticals and Roche entered a strategic global collaboration to develop, manufacture and distribute AT-527, an oral direct-acting antiviral RdRp inhibitor, for COVID-19. Atea received $350M upfront cash plus eligibility for up to $1B in additional payments ($330M tied to regulatory milestones). Atea retained US rights; Roche took ex-US rights. Deal terminated late 2021 after Phase 2 miss.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Roche Holding AG / Atea Pharmaceuticals, Inc. (this deal) | 2020 | $1.4B | — |
| Roche Holding AG / Chugai Pharmaceutical Co. Ltd. | 2002 | $1.4B | 100 |
| Roche Holding AG / Ventana Medical Systems Inc. | 2008 | $3.4B | 88 |
| Roche Holding AG / Corange Ltd. (Boehringer Mannheim Group) | 1997 | $11.0B | 88 |
| Roche Holding AG / Ventana Medical Systems Inc. | 2007 | $3.4B | 88 |
| Roche Holding AG / Foundation Medicine, Inc. | 2015 | $1.1B | 87 |
| Roche Holding AG / Foundation Medicine, Inc. | 2018 | $5.3B | 85 |
← Browse all deals · How we score deals
More: 2020 deals · Roche Holding AG deals · Infectious Disease deals